Dupont C, Betrouni N, Mordon S, Reyns N, Vermandel M.
5-ALA Photodynamic Therapy in Neurosurgery, Towards the Design of a Treatment Planning System: A Proof of Concept
IRBM, 2017. 38(1): p. 34-41.
5-ALA Photodynamic Therapy in Neurosurgery, Towards the Design of a Treatment Planning System: A Proof of Concept
IRBM, 2017. 38(1): p. 34-41.
ABSTRACT
Purpose: Glioblastoma (GBM) treatment still remains a complex challenge. Among alternatives or adjuvant therapies, photodynamic therapy (5-ALA PDT) appears to be a promising approach. 5-ALA PDT can be delivered intraoperatively, early after tumor resection, or interstitially according to brain tumor location. A treatment planning system was designed to manage dosimetry issues before PDT delivery.
Methods: The TPS was developed according to a specific workflow from stereotactic image registration to light fluence rate modeling. Here, we describe a proof of concept of a treatment planning system (TPS) dedicated to interstitial 5-ALA PDT. This tool enables the planning of a whole treatment in surgical stereotactic conditions. Stereotactic registration and dosimetry components are detailed and evaluated. The registration process is compared to a commercial solution (Leksell Gamma Plan®, Elekta®, Sweden) defined as the ground truth and dosimetry model implemented in our TPS and is compared to numerical simulations.
Results: Registration achieved a sub-millimetric mean relative error that matched the standard MRI resolution. Dosimetry comparison showed a negligible error between analytical and numerical models and enabled a validation of the dosimetry algorithm implemented.
Conclusions: A treatment planning system was designed to achieve 5-ALA PDT simulations before the patients underwent surgery. Similarly, for radiation therapy, we proposed a system to plan and evaluate the 5-ALA PDT dosimetry for optimizing treatment delivery. Although this system remains to be perfected, this preliminary work aimed to demonstrate the feasibility of planning 5-ALA PDT treatments in stereotactic conditions. Future improvements will mainly focus on the optimization of the treatment delivery, automatic segmentation and GPU-accelerated Monte-Carlo management to take into account GBM tissue heterogeneity.
DOI: 10.1016/j.irbm.2016.11.002
ScienceDirect Link | HAL Link
Purpose: Glioblastoma (GBM) treatment still remains a complex challenge. Among alternatives or adjuvant therapies, photodynamic therapy (5-ALA PDT) appears to be a promising approach. 5-ALA PDT can be delivered intraoperatively, early after tumor resection, or interstitially according to brain tumor location. A treatment planning system was designed to manage dosimetry issues before PDT delivery.
Methods: The TPS was developed according to a specific workflow from stereotactic image registration to light fluence rate modeling. Here, we describe a proof of concept of a treatment planning system (TPS) dedicated to interstitial 5-ALA PDT. This tool enables the planning of a whole treatment in surgical stereotactic conditions. Stereotactic registration and dosimetry components are detailed and evaluated. The registration process is compared to a commercial solution (Leksell Gamma Plan®, Elekta®, Sweden) defined as the ground truth and dosimetry model implemented in our TPS and is compared to numerical simulations.
Results: Registration achieved a sub-millimetric mean relative error that matched the standard MRI resolution. Dosimetry comparison showed a negligible error between analytical and numerical models and enabled a validation of the dosimetry algorithm implemented.
Conclusions: A treatment planning system was designed to achieve 5-ALA PDT simulations before the patients underwent surgery. Similarly, for radiation therapy, we proposed a system to plan and evaluate the 5-ALA PDT dosimetry for optimizing treatment delivery. Although this system remains to be perfected, this preliminary work aimed to demonstrate the feasibility of planning 5-ALA PDT treatments in stereotactic conditions. Future improvements will mainly focus on the optimization of the treatment delivery, automatic segmentation and GPU-accelerated Monte-Carlo management to take into account GBM tissue heterogeneity.
DOI: 10.1016/j.irbm.2016.11.002
ScienceDirect Link | HAL Link
